ProBioGen
-
Boehringer Ingelheim licenses ProBioGen's GlymaxX technology
Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive licensing agreement regarding ProBioGen’s GlymaxX technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (…
ProBioGen | 11 August 2011
-
GlymaxX: novel glyco-engineering technology
Probiogen launches its innovative Glyco-Engineering Technology "GlymaxX" for the generation of afucosylated antibodies with strongly increased potency. GlymaxX is a universally and rapidly applicable technology to enhance the ADCC effector funct…
ProBioGen | 28 November 2010
-
Probiogen Signs Therapeutic Protein Process Development Contract with Virdante
ProBioGen, a technology and service provider for the development and production of biopharmaceutical drug substances, has announced the signing of a contract with Virdante Biopharmaceuticals, a US-based biopharmaceutical development company. The f…
ProBioGen | 28 May 2010
